
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is well-positioned for growth as it continues to see success with its radiopharmaceuticals for imaging and treatment of various cancers. The company has a strong pipeline and a partnership with Advanced Nuclear Medicine Ingredients (ANMI) to expand its reach in the US market. The valuation methodology shows a potential market value of $6.66B, making it an attractive stock with an OUTPERFORM rating and a price objective of $22 per share.
Bears say
Telix Pharmaceuticals is a commercial stage biopharmaceutical company with a focus on developing and commercializing radiopharmaceuticals for the treatment of cancer. While the company has a pipeline of potential drugs, its current revenue is largely reliant on US sales of Illuccix, an imaging agent for prostate cancer. However, there are risks to meeting projected sales estimates and potential clinical and regulatory failures for the company's clinical stage programs, which could impact the company's financial performance and stock outlook.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares